Dynamic Changes in Fibrinogen and Prognosis of Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis

被引:23
作者
Shi, Jijun [1 ]
Shi, Rongfang [1 ]
Qin, Wenqian [1 ]
Zhang, Xia [1 ]
Liu, Huihui [1 ]
Xu, Jiaping [1 ]
Liu, Chun-Feng [1 ,2 ]
Cao, Yongjun [1 ]
机构
[1] Soochow Univ, Dept Neurol, Affiliated Hosp 2, Suzhou, Peoples R China
[2] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Acute ischemic stroke; Intravenous thrombolysis; Fibrinogen; Prognosis; EARLY NEUROLOGICAL DETERIORATION; HEALTH-CARE PROFESSIONALS; CARDIOVASCULAR-DISEASE; PLASMINOGEN-ACTIVATOR; PLASMA-FIBRINOGEN; HEMOSTATIC MARKERS; EARLY MANAGEMENT; MORTALITY; RISK; ASSOCIATION;
D O I
10.1007/s12640-020-00241-w
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This study aimed to investigate the association between dynamic changes in fibrinogen and the prognosis of acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT). We measured fibrinogen levels at admission and 24 h after IVT in 364 consecutively recruited AIS patients. The primary outcome was the composite measure of death or major disability (modified Rankin Scale score 3-6) at 3 months. During the 3-month follow-up, 127 (34.89%) patients experienced death or major disability. After multivariate adjustment, a >= 2.5% increase in fibrinogen was associated with an increased risk of the primary outcome (odds ratio [OR], 2.26; 95% confidence interval [CI] 1.08-4.75;ptrend = 0.030) when 2 extreme tertiles were compared. Each 1% increase in fibrinogen after IVT was associated with a 1% increase in the risk of the primary outcome (OR 1.01, 95% CI 1.00-1.03). Multivariable-adjusted spline regression revealed a linear dose-response relationship between fibrinogen changes after IVT and the primary outcome (pfor linearity = 0.032). The addition of fibrinogen changes to conventional risk factors improved the re-classification (but not discrimination) of the primary outcome (net reclassification index 27.6%,p = 0.011). These findings indicated that an increase in fibrinogen after IVT was associated with an increased risk of death or major disability in AIS patients, suggesting that monitoring the dynamic profile of fibrinogen levels may help neurologists improve stroke outcomes in clinical settings.
引用
收藏
页码:775 / 784
页数:10
相关论文
共 48 条
  • [1] CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL
    ADAMS, HP
    BENDIXEN, BH
    KAPPELLE, LJ
    BILLER, J
    LOVE, BB
    GORDON, DL
    MARSH, EE
    KASE, CS
    WOLF, PA
    BABIKIAN, VL
    LICATAGEHR, EE
    ALLEN, N
    BRASS, LM
    FAYAD, PB
    PAVALKIS, FJ
    WEINBERGER, JM
    TUHRIM, S
    RUDOLPH, SH
    HOROWITZ, DR
    BITTON, A
    MOHR, JP
    SACCO, RL
    CLAVIJO, M
    ROSENBAUM, DM
    SPARR, SA
    KATZ, P
    KLONOWSKI, E
    CULEBRAS, A
    CAREY, G
    MARTIR, NI
    FICARRA, C
    HOGAN, EL
    CARTER, T
    GURECKI, P
    MUNTZ, BK
    RAMIREZLASSEPAS, M
    TULLOCH, JW
    QUINONES, MR
    MENDEZ, M
    ZHANG, SM
    ALA, T
    JOHNSTON, KC
    ANDERSON, DC
    TARREL, RM
    NANCE, MA
    BUDLIE, SR
    DIERICH, M
    HELGASON, CM
    HIER, DB
    SHAPIRO, RA
    [J]. STROKE, 1993, 24 (01) : 35 - 41
  • [2] Statistical Analysis of the Primary Outcome in Acute Stroke Trials
    Bath, Philip M. W.
    Lees, Kennedy R.
    Schellinger, Peter D.
    Altman, Hernan
    Bland, Martin
    Hogg, Cheryl
    Howard, George
    Saver, Jeffrey L.
    [J]. STROKE, 2012, 43 (04) : 1171 - 1178
  • [3] Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: results from a multicenter, randomized, parallel-group and controlled clinical trial
    Cao Yong-jun
    Zhang Xia
    Wang Wan-hua
    Zhai Wan-qing
    Qian Ju-fen
    Wang Jian-sheng
    Chen Jun
    You Nian-xing
    Zhao Zhong
    Wu Qiu-yi
    Xu Yuan
    Yuan Lei
    Li Rui-xia
    Liu Chun-feng
    [J]. CHINESE MEDICAL JOURNAL, 2013, 126 (21) : 4060 - 4065
  • [4] Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and infl ammation
    Chamorro, Angel
    Dirnagl, Ulrich
    Urra, Xabier
    Planas, Anna M.
    [J]. LANCET NEUROLOGY, 2016, 15 (08) : 869 - 881
  • [5] ANALYSIS OF COAGULATION AND FIBRINOLYSIS DURING INTRAVENOUS-INFUSION OF RECOMBINANT HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
    COLLEN, D
    BOUNAMEAUX, H
    DECOCK, F
    LIJNEN, HR
    VERSTRAETE, M
    [J]. CIRCULATION, 1986, 73 (03) : 511 - 517
  • [6] FACTOR XIIIA BINDING TO ACTIVATED PLATELETS IS MEDIATED THROUGH ACTIVATION OF GLYCOPROTEIN IIB-IIIA
    COX, AD
    DEVINE, DV
    [J]. BLOOD, 1994, 83 (04) : 1006 - 1016
  • [7] Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality - An individual participant meta-analysis
    Danesh, J
    Lewington, S
    Thompson, SG
    Lowe, GDO
    Collins, R
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14): : 1799 - 1809
  • [8] Fibrinogen as a key regulator of inflammation in disease
    Davalos, Dimitrios
    Akassoglou, Katerina
    [J]. SEMINARS IN IMMUNOPATHOLOGY, 2012, 34 (01) : 43 - 62
  • [9] Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke
    del Zoppo, Gregory J.
    Levy, David E.
    Wasiewski, Warren W.
    Pancioli, Arthur M.
    Demchuk, Andrew M.
    Trammel, James
    Demaerschalk, Bart M.
    Kaste, Markku
    Albers, Gregory W.
    Ringelstein, Eric B.
    [J]. STROKE, 2009, 40 (05) : 1687 - 1691
  • [10] The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke
    Dong, Qiang
    Dong, Yi
    Liu, Liping
    Xu, Anding
    Zhang, Yusheng
    Zheng, Huaguang
    Wang, Yongjun
    [J]. STROKE AND VASCULAR NEUROLOGY, 2017, 2 (03) : 147 - 159